Levodopa/Benserazid Ct (Benserazide, Levodopa)

Levodopa/Benserazide is used in the management of Parkinsonian disorders by enhancing central dopaminergic activity.

• Parkinson's disease (early stage): improves motor function and reduces rigidity.
• Parkinson's disease (advanced stage): helps control fluctuations in symptom control.
• Levodopa‑responsive Parkinsonism: provides symptomatic relief when dopamine deficiency is evident.

• Levodopa is a precursor that crosses the blood‑brain barrier and is decarboxylated to dopamine within the central nervous system, restoring depleted neurotransmitter levels. Benserazide, a peripheral aromatic L‑amino acid decarboxylase inhibitor, blocks the conversion of levodopa to dopamine outside the brain, thereby increasing the amount of levodopa available for central conversion and reducing peripheral side effects.

Levodopa/Benserazide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Orthostatic hypotension: dizziness upon standing.
• Dyskinesia: involuntary movements, especially with long‑term use.
• Hallucinations: visual disturbances, more common in older patients.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity.
• Severe cardiac arrhythmias: rare but potentially fatal.
• Severe psychiatric disturbances: including psychosis or severe depression.

When prescribing Levodopa/Benserazide, clinicians should observe several precautionary measures to ensure safe use.

• Assess renal and hepatic function: dose may need adjustment in impairment.
• Monitor for cardiovascular disease: risk of orthostatic hypotension and arrhythmias.
• Evaluate psychiatric history: potential for hallucinations or psychosis.
• Use with caution in elderly patients: increased susceptibility to side effects.
• Store at room temperature: keep in original container, protect from moisture and light.

Levodopa/Benserazide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis.
• Antipsychotics (e.g., haloperidol): may diminish antiparkinson effect.
• High‑protein meals: reduce levodopa absorption, decreasing therapeutic benefit.

Moderate Interactions (Monitor Closely)

• COMT inhibitors (e.g., entacapone): may increase levodopa levels, requiring dose adjustment.
• Antihypertensive agents: additive effect on blood pressure, monitor for hypotension.
• SSRIs and SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibitors.